Ipsen Biopharmaceuticals, Inc., a prominent player in the biopharmaceutical industry, is headquartered in the United States and operates extensively across North America and Europe. Founded in 1929, Ipsen has established itself as a leader in the development of innovative therapies, particularly in oncology, neuroscience, and rare diseases. The company is renowned for its core products, including Somatuline® and Dysport®, which are distinguished by their unique formulations and targeted delivery mechanisms. Ipsen's commitment to research and development has led to significant milestones, including the expansion of its product portfolio and strategic partnerships that enhance its market position. With a focus on patient-centric solutions, Ipsen continues to achieve notable recognition within the biopharmaceutical sector, driving advancements that improve patient outcomes globally.
We don't have data for Ipsen Biopharmaceuticals, Inc., but we can show you information about their parent organization instead.
View parent company